Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

66 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma.
Fowler NH, Samaniego F, Jurczak W, Ghosh N, Derenzini E, Reeves JA, Knopińska-Posłuszny W, Cheah CY, Phillips T, Lech-Maranda E, Cheson BD, Caimi PF, Grosicki S, Leslie LA, Chavez JC, Fonseca G, Babu S, Hodson DJ, Shao SH, Burke JM, Sharman JP, Law JY, Pagel JM, Miskin HP, Sportelli P, O'Connor OA, Weiss MS, Zinzani PL. Fowler NH, et al. Among authors: law jy. J Clin Oncol. 2021 May 20;39(15):1609-1618. doi: 10.1200/JCO.20.03433. Epub 2021 Mar 8. J Clin Oncol. 2021. PMID: 33683917 Free PMC article. Clinical Trial.
Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions.
Orellana-Noia VM, Reed DR, McCook AA, Sen JM, Barlow CM, Malecek MK, Watkins M, Kahl BS, Spinner MA, Advani R, Voorhees TJ, Snow A, Grover NS, Ayers A, Romancik J, Liu Y, Huntington SF, Chavez JC, Saeed H, Lazaryan A, Raghunathan V, Spurgeon SE, Ollila TA, Del Prete C, Olszewski A, Ayers EC, Landsburg DJ, Echalier B, Lee J, Kamdar M, Caimi PF, Fu T, Liu J, David KA, Alharthy H, Law J, Karmali R, Shah H, Stephens DM, Major A, Rojek AE, Smith SM, Yellala A, Kallam A, Nakhoda S, Khan N, Sohail MA, Hill BT, Barrett-Campbell O, Lansigan F, Switchenko J, Cohen J, Portell CA. Orellana-Noia VM, et al. Blood. 2022 Jan 20;139(3):413-423. doi: 10.1182/blood.2021012888. Blood. 2022. PMID: 34570876 Free PMC article.
The impact of bridging therapy prior to CD19-directed chimeric antigen receptor T-cell therapy in patients with large B-cell lymphoma.
Lutfi F, Holtzman NG, Kansagra AJ, Mustafa Ali M, Bukhari A, Yan J, Samanta S, Gottlieb D, Kim DW, Matsumoto LR, Gahres N, Ruehle K, Lee ST, Law JY, Kocoglu MH, Atanackovic D, Yared JA, Hardy NM, Molitoris J, Mohindra P, Rapoport AP, Dahiya S. Lutfi F, et al. Among authors: law jy. Br J Haematol. 2021 Nov;195(3):405-412. doi: 10.1111/bjh.17738. Epub 2021 Sep 9. Br J Haematol. 2021. PMID: 34500492
Impaired immune response to COVID-19 vaccination in patients with B-cell malignancies after CD19 CAR T-cell therapy.
Dahiya S, Luetkens T, Lutfi F, Avila S, Iraguha T, Margiotta P, Hankey KG, Lesho P, Law JY, Lee ST, Baddley J, Kocoglu M, Yared JA, Hardy NM, Rapoport AP, Atanackovic D. Dahiya S, et al. Among authors: law jy. Blood Adv. 2022 Jan 25;6(2):686-689. doi: 10.1182/bloodadvances.2021006112. Blood Adv. 2022. PMID: 34941995 Free PMC article. No abstract available.
Low utility of the H-Score and HLH-2004 criteria to identify patients with secondary hemophagocytic lymphohistiocytosis after CAR-T cell therapy for relapsed/refractory diffuse large B-Cell lymphoma.
Kim DW, Bukhari A, Lutfi F, Zafforoni F, Merechi F, Mustafa Ali MK, Gottlieb D, Lee ST, Kocoglu MH, Hardy NM, Yared J, Rapoport AP, Dahiya S, Law JY. Kim DW, et al. Among authors: law jy. Leuk Lymphoma. 2022 Jun;63(6):1339-1347. doi: 10.1080/10428194.2021.2024817. Epub 2022 Jan 19. Leuk Lymphoma. 2022. PMID: 35045791
A Seemingly Solitary Bone Lesion.
Bansal R, Rentz M, Law JY. Bansal R, et al. Among authors: law jy. JAMA Oncol. 2016 Jun 1;2(6):815-6. doi: 10.1001/jamaoncol.2016.1068. JAMA Oncol. 2016. PMID: 27149699 No abstract available.
66 results